Investing & trading with exchange-traded funds (ETFs) and closed-end funds (CEFs). Strategies & analysis but no buy or sell recommendations.

Visit SeekingAlpha ETFs

Oncolytics Announces Breakthrough in Cancer Treatment Trials

Posted on May 22, 2008

Oncolytics Biotech Inc.'s (ONCY) cancer fighting virus, Reolysin, is the key to the company's future value, says Blackmont analyst Wayne Schnarr.He initiated coverage on Oncolytics with a speculative buy rating and C$3.25 price target, representing upside of roughly 80% on the stock's current C$1.84 value. ...

Original article link


analyst , biotech , speculative